High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2185-2190

  Reijm, E A ^a   Timmermans, A M ^a   Look, M P ^a   Meijer van Gelder, M E ^a   Stobbe, C K ^c   van Deurzen, C H M ^a,b   M Martens, J W ^a   Sleijfer, S ^a   Foekens, J A ^a   Berns, P M J J ^a   Jansen, M P H M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Endocrine therapy resistance; EZH2; Immunohistochemistry; Metastatic breast cancer; Personalized medicine; Tissue microarray

Indexed keywords

TAMOXIFEN; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; MESSENGER RNA; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL PREDICTION; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; MIDDLE AGED; NEOPLASM METASTASIS; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RNA, MESSENGER; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84923107794     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu391     Document Type: Article

References (34)

1. Thompson AM, Jordan LB, Quinlan P et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010; 12: R92.
2. Gong Y, Han EY, Guo M et al. Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 2011; 117: 705-713.
3. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30: 587-592.
4. Pancholi S, Lykkesfeldt AE, Hilmi C et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 2008; 15: 985-1002.
5. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29: 4452-4461.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
7. Hong DS, Bowles DW, Falchook GS et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4173-4182.
8. Jansen MP, Foekens JA, van Staveren IL et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-740.
9. Reijm EA, Jansen MP, Ruigrok-Ritstier K et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat 2011; 125: 387-394.
10. Bracken AP, Dietrich N, Pasini D et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
11. Schuettengruber B, Chourrout D, Vervoort M et al. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128: 735-745.
12. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
13. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
14. Raaphorst FM, van Kemenade FJ, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157: 709-715.
15. Visser HP, Gunster MJ, Kluin-Nelemans HC et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950-958.
16. Raman JD, Mongan NP, Tickoo SK et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005; 11: 8570-8576.
17. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005; 16: 349-353.
18. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-273.
19. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
20. Collett K, Eide GE, Arnes J et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 1168-1174.
21. Raaphorst FM, Meijer CJ, Fieret E et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5: 481-488.
22. Eskander RN, Ji T, Huynh B et al. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 2013; 23: 997-1005.
23. Hubaux R, Thu KL, Coe BP et al. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thorac Oncol 2013; 8: 1102-1106.
24. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
25. McShane LM, Altman DG, Sauerbrei W et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229-235.
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
27. Alford SH, Toy K, Merajver SD, Kleer CG. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 2012; 132: 429-437.
28. Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
29. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
30. Rokita M, Stec R, Bodnar L et al. Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. Oncol Targets Ther 2013; 6: 967-976.
31. Henriksen KL, Rasmussen BB, Lykkesfeldt AE et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007; 60: 397-404.
32. Chan P, Moller A, Liu MC et al. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Res 2011; 13: R19.
33. Sato T, Kaneda A, Tsuji S et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 2013; 3: 1911.
34. Knutson SK, Warholic NM, Wigle TJ et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 2013; 110: 7922-7927.